Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 14/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481621 | 0.83 | MTOR (0.58) | ATRALDH1A1CYP2C19 | |
| SCHEMBL481664 | 0.82 | FYN (0.44) | MAP3K11ATRACVR1ALDH1A1FTO | |
| SCHEMBL481704 | 0.81 | FYN (0.55) | ATRACVR1ALDH1A1KDM5B | |
| SCHEMBL481545 | 0.81 | FYN (0.55) | ATRACVR1ALDH1A1KDM5B | |
| SCHEMBL481543 | 0.81 | FYN (0.55) | ATRACVR1ALDH1A1KDM5B | |
| SCHEMBL481888 | 0.80 | MTOR (0.55) | ATRACVR1FTOKDM5BKDM2A | |
| SCHEMBL2360980 | 0.80 | MAP3K11 (0.57) | MAP3K11 | |
| SCHEMBL481836 | 0.79 | FYN (0.44) | MAP3K11ATRACVR1CYP2C19KDM5B | |
| SCHEMBL482532 | 0.78 | GSK3B (0.47) | ACVR1 | |
| SCHEMBL481278 | 0.78 | FYN (0.43) | ATRACVR1ALDH1A1FTOKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | claimed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | claimed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | claimed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3659599-B1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR USE IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME | SIGNAL PHARM LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3466423-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3659599-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2768500-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2817029-B1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | MAP3K11 94/4885ATR 327/4885LOXL3 3218/4885 |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | MTOR, TTK, BRCA1 | MAP3K11 41/4885ATR 273/4885LOXL3 4385/4885 |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MAP3K11 82/4885ATR 200/4885LOXL3 4506/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MAP3K11 44/4885ATR 562/4885LOXL3 992/4885 |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MAP3K11 82/4885ATR 200/4885LOXL3 4506/4885 |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | MTOR, TTK, RICTOR | MAP3K11 82/4885ATR 200/4885LOXL3 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.